Get the Stockscreener App
7.56
10.04%
0.69
After Hours:
7.56
Design Therapeutics Inc stock is traded at $7.56, with a volume of 1.26M.
It is up +10.04% in the last 24 hours and up +16.49% over the past month.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
See More
Previous Close:
$6.87
Open:
$6.8
24h Volume:
1.26M
Relative Volume:
6.35
Market Cap:
$430.53M
Revenue:
-
Net Income/Loss:
$-66.86M
P/E Ratio:
-6.30
EPS:
-1.2
Net Cash Flow:
$-58.82M
1W Performance:
+12.84%
1M Performance:
+16.49%
6M Performance:
+127.03%
1Y Performance:
+30.57%
1-Day Range:
$6.80
$7.93
1-Week Range:
$6.16
$7.93
52-Week Range:
$2.60
$7.93
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics Inc
Sector
Industry
Phone
858-293-4900
Address
6005 HIDDEN VALLEY ROAD, CARLSBAD
Compare DSGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
7.56 | 391.34M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-15-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-15-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Aug-15-23 | Downgrade | Wedbush | Outperform → Neutral |
| May-04-23 | Upgrade | Goldman | Sell → Neutral |
| Jun-10-22 | Initiated | Wedbush | Outperform |
| May-02-22 | Initiated | RBC Capital Mkts | Outperform |
| Jan-19-22 | Initiated | Goldman | Sell |
| Apr-20-21 | Initiated | Goldman | Neutral |
| Apr-20-21 | Initiated | Piper Sandler | Overweight |
| Apr-20-21 | Initiated | SVB Leerink | Outperform |
View All
Design Therapeutics Inc Stock (DSGN) Latest News
Design Therapeutics (NASDAQ:DSGN) Price Target Raised to $6.00 - Defense World
Why retail investors favor Design Therapeutics Inc. stockWeekly Stock Recap & Accurate Entry/Exit Alerts - newser.com
Published on: 2025-11-08 10:43:24 - newser.com
How to interpret RSI for Design Therapeutics Inc. stockWeekly Risk Report & Advanced Swing Trade Entry Plans - newser.com
Can Design Therapeutics Inc. stock sustain institutional interestJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Technical signs of recovery in Design Therapeutics Inc.Risk Management & Daily Profit Focused Screening - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio charts2025 Technical Overview & Free Risk Controlled Daily Trade Plans - newser.com
What indicators show strength in Design Therapeutics Inc.Market Sentiment Review & Long-Term Growth Plans - newser.com
Design Therapeutics Posts Narrower Loss And Expands Research Pipeline - Finimize
DSGN: RBC Capital Raises Price Target for Design Therapeutics | - GuruFocus
RBC Raises Price Target on Design Therapeutics to $6 From $5, Keeps Sector Perform, Speculative Risk - MarketScreener
Is Design Therapeutics Inc. stock poised for growthEarnings Risk Report & Verified Trade Idea Suggestions - newser.com
How high can Design Therapeutics Inc. stock goMarket Rally & Expert-Curated Trade Recommendations - newser.com
Why Design Therapeutics Inc. stock could outperform in 2025Entry Point & Low Risk High Reward Trade Ideas - fcp.pa.gov.br
How to integrate Design Therapeutics Inc. into portfolio analysis toolsJuly 2025 Action & Smart Allocation Stock Tips - newser.com
Design Therapeutics Reports Q3 2025 Financial Results - TipRanks
Design Therapeutics unveils DT-818 for myotonic dystrophy treatment By Investing.com - Investing.com Nigeria
Should you wait for a breakout in Design Therapeutics Inc.Trade Performance Summary & Smart Swing Trading Techniques - newser.com
Will Design Therapeutics Inc. stock outperform tech sector in 2025Rate Hike & Momentum Based Trading Ideas - fcp.pa.gov.br
Forecasting Design Therapeutics Inc. price range with options data2025 Short Interest & Capital Efficiency Focused Ideas - newser.com
Developing predictive dashboards with Design Therapeutics Inc. dataMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Design Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Design Therapeutics' reports lower-than-expected Q3 loss - MarketScreener
Design Therapeutics unveils DT-818 for myotonic dystrophy treatment - Investing.com
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results - The Manila Times
Design (NASDAQ: DSGN) gains ex-US regulatory clearance; DT-818 dosing DM1 H1 2026 - Stock Titan
Is Design Therapeutics Inc. forming a bottoming baseShort Setup & Smart Money Movement Alerts - newser.com
What recovery options are there for Design Therapeutics Inc.2025 Macro Impact & Consistent Income Trade Ideas - newser.com
Regression analysis insights on Design Therapeutics Inc. performance2025 Year in Review & Short-Term Trading Opportunity Alerts - newser.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 - Yahoo Finance
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How to recover losses in Design Therapeutics Inc. stockWeekly Trade Report & Weekly Sector Rotation Insights - newser.com
Design Therapeutics, Inc. (NASDAQ:DSGN) Short Interest Update - MarketBeat
Design Therapeutics Inc Stock (DSGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):